On September 18, 2014, Nazare, Marc; Halland, Nis; Schmidt, Friedemann; Kleemann, Heinz-Werner; Weiss, Tilo; Saas, Joachim; Struebing, Carsten published a patent.Synthetic Route of 98138-75-1 The title of the patent was Preparation of N-[4-(azaindazol-6-yl)-phenyl]-sulfonamides as SGK1 inhibitors. And the patent contained the following:
The title compounds I [Ar = (un)substituted Ph, 5-6 membered monocyclic, aromatic, heterocyclic group which comprises 1-3 identical or different ring heteroatoms selected from the series consisting of N, O and S, and is bonded via a ring C atom; n = 0-2; X = N, CH; Z = a bond, O, S, (un)substituted NH; R1 = H, (un)substituted NH2, NHC(O)NH2, etc.; R2 = halo, alkyl, alkoxy, CN; R3 = H, alkyl, -alkyl-R (R = (un)substituted 3-12 membered, monocyclic or bicyclic, saturated, partially unsaturated or aromatic, cyclic group which comprises 0-3 identical or different ring heteroatoms selected from N, O and S)] which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism, were prepared E.g., a multi-step synthesis of II, starting from 2,5-dichlorobenzenesulfonyl chloride and 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine, was described. Exemplified compounds I were tested for serum and glucocorticoid-regulated kinase 1 (SGK-1) inhibitory activity (data given). The invention furthermore relates to processes for the preparation of compounds I, their use as pharmaceuticals, and pharmaceutical compositions comprising them. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Synthetic Route of 98138-75-1
The Article related to azaindazolylphenyl sulfonamide preparation sgk1 inhibitor antiinflammatory antirheumatic antiarthritic, degenerative joint disorder osteoarthritis treatment azaindazolylphenyl sulfonamide preparation, serum glucocorticoid regulated kinase sgk inhibitor azaindazolylphenyl sulfonamide preparation and other aspects.Synthetic Route of 98138-75-1
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics